Incannex Healthcare (IHL) recruits first patients to its IHL-42X phase 2b OSA clinical trial
Incannex Healthcare (ASX: IHL), a pharmaceutical development company, has taken a major step towards the advancement of IHL-42X phase 2b obstructive sleep apnoea (‘OSA’) clinical trial by announcing the recruitment of first patients of the study. The study is aiming to investigate the safety and efficacy of the drug candidate in the treatment of OSA.